Deal Tracker · Regions

GCC pharma distribution deals

21 distribution deals in the GCC tracked by EPT (2025–2026). Most active: Mubadala Bio, SPIMACO, Accord Healthcare & ADCAN Pharma. Latest: Korea Pharmbio → Ashro Drug Store (Distribution, 3 Nov 2026).

21
deals tracked
18
announced in 2026
—
values undisclosed
100%
distribution, the top deal type
  • EPT has tracked 21 GCC pharma distribution deals (2025–2026), 18 of them announced in 2026.
  • The countries that appear most often are UAE (14), Saudi Arabia (11), Jordan (3) & Kuwait (3).
  • None of these deals disclosed a value, which is common for licensing and distribution agreements in these markets.
  • The most active companies: Mubadala Bio (4) & SPIMACO (2).

Most active companies

Mubadala Bio (4) · SPIMACO (2)

Countries involved

UAE (14) · Saudi Arabia (11) · Jordan (3) · Kuwait (3) · Oman (3) · Qatar (3)

Questions

How many GCC pharma distribution deals has EPT tracked?
21 as of 3 Nov 2026, covering 2025–2026; 18 were announced in 2026. The most recent is Korea Pharmbio → Ashro Drug Store (Distribution, 3 Nov 2026).
Which companies are most active in GCC pharma distribution deals?
Mubadala Bio (4 deals), SPIMACO (2 deals).
Which countries appear most in GCC pharma distribution deals?
UAE (14), Saudi Arabia (11), Jordan (3), Kuwait (3), Oman (3), Qatar (3) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)